Progression of epithelial cancers predominantly proceeds by collective invasion of cell groups with coordinated cell–cell junctions and multicellular cytoskeletal activity. Collectively invading breast cancer cells express the gap junction protein connexin-43 (Cx43), yet whether Cx43 regulates collective invasion remains unclear. We here show that Cx43 mediates gap-junctional coupling between collectively invading breast cancer cells and, via hemichannels, adenosine nucleotide/nucleoside release into the extracellular space. Using molecular interference and rescue strategies, we identify that Cx43 hemichannel function, but not intercellular communication, induces leader cell activity and collective migration through the engagement of the adenosine receptor 1 (ADORA1) and AKT signaling. Accordingly, pharmacological inhibition of ADORA1 or AKT signaling caused leader cell collapse and halted collective invasion. ADORA1 inhibition further reduced local invasion of orthotopic mammary tumors in vivo, and joint up-regulation of Cx43 and ADORA1 in breast cancer patients correlated with decreased relapse-free survival. This identifies autocrine purinergic signaling, through Cx43 hemichannels, as a critical pathway in leader cell function and collective invasion.
Skip Nav Destination
Close
Article navigation
5 October 2020
Article|
August 10 2020
Collective invasion induced by an autocrine purinergic loop through connexin-43 hemichannels
Antoine A. Khalil,
Antoine A. Khalil
1
Department of Dermatology and Graduate School of Life Science, University of Wuerzburg, Wuerzburg, Germany
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Search for other works by this author on:
Olga Ilina,
Olga Ilina
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Search for other works by this author on:
Angela Vasaturo,
Angela Vasaturo
3
Department of Tumor Immunology, Radboud University Medical Center, Nijmegen, Netherlands
Search for other works by this author on:
Jan-Hendrik Venhuizen,
Jan-Hendrik Venhuizen
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Search for other works by this author on:
Manon Vullings,
Manon Vullings
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Search for other works by this author on:
Victor Venhuizen,
Victor Venhuizen
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Search for other works by this author on:
Ab Bilos,
Ab Bilos
4
Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Search for other works by this author on:
Carl G. Figdor,
Carl G. Figdor
3
Department of Tumor Immunology, Radboud University Medical Center, Nijmegen, Netherlands
Search for other works by this author on:
Paul N. Span,
Paul N. Span
5
Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands
Search for other works by this author on:
Peter Friedl
1
Department of Dermatology and Graduate School of Life Science, University of Wuerzburg, Wuerzburg, Germany
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
6
David H. Koch Center for Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
7
Cancer Genomics Center, Utrecht, Netherlands
Correspondence to Peter Friedl: peter.friedl@radboudumc.nl
Search for other works by this author on:
Antoine A. Khalil
1
Department of Dermatology and Graduate School of Life Science, University of Wuerzburg, Wuerzburg, Germany
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Olga Ilina
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Angela Vasaturo
3
Department of Tumor Immunology, Radboud University Medical Center, Nijmegen, Netherlands
Jan-Hendrik Venhuizen
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Manon Vullings
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Victor Venhuizen
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Ab Bilos
4
Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Carl G. Figdor
3
Department of Tumor Immunology, Radboud University Medical Center, Nijmegen, Netherlands
Paul N. Span
5
Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands
Peter Friedl
1
Department of Dermatology and Graduate School of Life Science, University of Wuerzburg, Wuerzburg, Germany
2
Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
6
David H. Koch Center for Genitourinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
7
Cancer Genomics Center, Utrecht, Netherlands
Correspondence to Peter Friedl: peter.friedl@radboudumc.nl
Received:
December 02 2019
Revision Received:
May 23 2020
Accepted:
June 30 2020
Online Issn: 1540-8140
Print Issn: 0021-9525
Funding:
European Research Council
(617430-DEEPINSIGHT)
© 2020 Khalil et al.
2020
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
J Cell Biol (2020) 219 (10): e201911120.
Article history
Received:
December 02 2019
Revision Received:
May 23 2020
Accepted:
June 30 2020
Citation
Antoine A. Khalil, Olga Ilina, Angela Vasaturo, Jan-Hendrik Venhuizen, Manon Vullings, Victor Venhuizen, Ab Bilos, Carl G. Figdor, Paul N. Span, Peter Friedl; Collective invasion induced by an autocrine purinergic loop through connexin-43 hemichannels. J Cell Biol 5 October 2020; 219 (10): e201911120. doi: https://doi.org/10.1083/jcb.201911120
Download citation file:
Close
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Advertisement
Advertisement